All In Biotech

Drug Trial Radar · NCT02950480

Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

4

Actual

Start

Mar 13, 2017

Primary completion

Dec 20, 2018

Study completion Dec 20, 2018

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 2 arm, 90 patient (45 per cohort) trial in patients with breast cancer who will be undergoing mastectomy with immediate tissue-expander reconstruction to determine whether treatment with zafirlukast (20mg PO BID) can reduce or prevent the development of capsular contracture.

Conditions

  • Breast Cancer

Interventions

  • zafirlukastDrug

    Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.

  • Standard of Care (no intervention)Other

    Standard of Care (no intervention)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Capsular ThicknessTime frame: Day 44 to Day 126

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.